Umoja wa Ulaya - Kifaransa - EMA (European Medicines Agency)

pfizer europe ma eeig - neisseria meningitidis du sérogroupe b fhbp (recombinant lipidees fhbp (protéine de liaison du facteur h)) sous-famille a ; neisseria meningitidis du sérogroupe b sous-famille de fhbp (recombinant lipidees fhbp (protéine de liaison du facteur h)) b - méningite méningococcique - bacterial vaccines, meningococcal vaccines - trumenba est indiqué pour l’immunisation active des individus 10 ans et plus pour empêcher les méningococcies invasives dues à neisseria meningitidis du sérogroupe b. l'utilisation de ce vaccin doit être en conformité avec les recommandations officielles.

Umoja wa Ulaya - Kifaransa - EMA (European Medicines Agency)

ceva santé animale - influenza a virus/human strain: a/jena/vi5258/2009 (h1n1)pdm09, inactivated - immunologiques, vaccins viraux inactivés pour les porcs, virus de la grippe porcine - les cochons - active la vaccination des porcs à partir de l'âge de 8 semaines à partir de la contre la pandémie h1n1 de la grippe porcine virus de réduire virale poumon de la charge et de l'excrétion virale. the vaccine can be used during pregnancy up to three weeks before expected farrowing and during lactation lactation.

Umoja wa Ulaya - Kifaransa - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rfp-lt) and avian encephalomyelitis virus, strain calnek 1143 (ae) - immunologicals for aves, live viral vaccines, domestic fowl - poulet - for active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.

Umoja wa Ulaya - Kifaransa - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - les cochons - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Umoja wa Ulaya - Kifaransa - EMA (European Medicines Agency)

ceva santé animale - clostridium perfringens type c, beta1 toxoid / clostridium perfringens, type a, alpha toxoid / clostridium perfringens, type a, beta2 toxoid / escherichia coli, fimbrial adhesin f4ab / escherichia coli, fimbrial adhesin f4ac / escherichia coli, fimbrial adhesin f5 / escherichia coli, fimbrial adhesin f6 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - les cochons - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:-           clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6-           clinical signs (diarrhoea during the first days of life) associated with clostridium perfringens type a expressing alpha and beta 2 toxins-           clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by clostridium perfringens type c expressing beta1 toxin.

Umoja wa Ulaya - Kifaransa - EMA (European Medicines Agency)

novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. l'utilisation de ce vaccin doit être en conformité avec les recommandations officielles. nuvaxovid xbb. 5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. l'utilisation de ce vaccin doit être en conformité avec les recommandations officielles.

Umoja wa Ulaya - Kifaransa - EMA (European Medicines Agency)

laboratorios hipra, s.a. - clostridioides difficile toxoid a, clostridioides difficile toxoid b, clostridium perfringens, type a, alpha toxoid - immunologicals for suidae, inactivated bacterial vaccines for pigs, clostridium - les cochons - for the passive immunisation of neonatal piglets by means of the active immunisation of breeding sows and gilts:- to prevent mortality and reduce clinical signs and macroscopic lesions caused by clostridioides difficile toxins a and b. - to reduce clinical signs and macroscopic lesions caused by clostridium perfringens type a, alpha toxin.

Umoja wa Ulaya - Kifaransa - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - pneumococcal polysaccharide conjugate vaccine (adsorbed) - infections pneumococciques - pneumococcus, purified polysaccharides antigen conjugated - vaxneuvance is indicated for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age. vaxneuvance is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. voir les sections 4. 4 et 5. 1 pour des informations sur la protection contre les sérotypes pneumococciques spécifiques. the use of vaxneuvance should be in accordance with official recommendations.

Umoja wa Ulaya - Kifaransa - EMA (European Medicines Agency)

intervet international bv - souches de virus de l'influenza équine: a / équidé-2 / afrique du sud / 4/03, a / équidé-2 / newmarket / 2/93, anatoxine tétanique - virus de la grippe équine + clostridium - les chevaux - immunisation active des chevaux à partir de l'âge de six mois contre la grippe équine afin de réduire les signes cliniques et l'excrétion du virus après l'infection, et immunisation active contre le tétanos pour prévenir la mortalité.

Umoja wa Ulaya - Kifaransa - EMA (European Medicines Agency)

intervet international bv - leptospira interrogans sérogroupe canicola sérotype portland-vere (souche ca-12-000), l. interrogans sérogroupe icterohaemorrhagiae sérovar copenhageni (souche ic-02-001), l. interrogans sérogroupe australis sérotype bratislava (souche-05-073), l. kirschneri sérogroupe grippotyphosa sérotype dadas (souche gr-01-005) - immunologiques - chiens - pour active la vaccination des chiens contre:leptospira interrogans sérogroupe canicola des sérovars canicola pour réduire l'infection et l'excrétion urinaire;l. interrogans sérogroupe icterohaemorrhagiae sérovar copenhageni pour réduire l'infection et l'excrétion urinaire;l. interrogans sérogroupe australis sérotype bratislava pour réduire l'infection;l. kirschneri sérogroupe grippotyphosa sérovar bananal / lianguang pour réduire l'infection et l'excrétion urinaire.